The Milpark Hospital is a private hospital in western Parktown, Johannesburg, in the area known as Milpark, and owned by Netcare Limited. It has a level 1 accredited trauma unit, and cardiology and cardio-thoracic services. It has 346 beds, of which 95 are used for high care and intensive care. The hospital also houses the only Gamma Knife unit in South Africa.Nelson Mandela was treated at the hospital for an acute respiratory infection in January 2011 and underwent a laparoscopy there in February 2012.InIn February 2009, South African sprinter Oscar Pistorius was treated at the hospital after a serious boating accident.On 2 April 2018, Winnie Madikizela-Mandela died at the hospital.In 2021 Shona Ferguson died at the hospital due to COVID-19 complications. He is survived by his wife, actress Connie Ferguson and two daughters .
BACKGROUND:Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract illness (LRTI) in older adults. RSV prefusion F (RSVpreF) is a bivalent stabilized prefusion F vaccine containing RSV-A and RSV-B antigens. In this phase 3 trial in persons aged ≥60 years, RSVpreF demonstrated vaccine efficacy (VE) of 88.9% and 77.8% against RSV-associated LRTI with ≥3 symptoms at the end of RSV seasons 1 and 2, respectively. We describe final safety and efficacy results and present immunogenicity data. METHODS:This study was conducted over 2 RSV seasons. Participants were randomized (1:1) to RSVpreF 120-µg or placebo. A secondary objective was to describe RSVpreF immunogenicity 1 month post-vaccination and before season 2 visits in participants from the United States and Japan. RESULTS:One-month post-vaccination neutralization titer geometric mean fold rise (GMFR) was 12.1 for combined RSV-A/RSV-B. Geometric mean titers decreased at the preseason 2 visit but remained substantially higher than baseline (RSV-A/RSV-B GMFR = 4.7). One month post-vaccination, GMFRs for RSV-A/RSV-B neutralizing responses were 12.0 to 13.0 for subgroups stratified by age (60-69, 70-79, ≥80 years). RSV-A/RSV-B GMFRs in participants with prespecified chronic conditions were generally similar to those without (range, 11.4-14.4). A consistent favorable safety profile and durable VE were seen through 2 RSV seasons. CONCLUSIONS:High RSV neutralizing titers were observed 1 month after RSVpreF vaccination in persons aged ≥60 years, with similarly robust responses across subgroups. These immune responses corresponded with high RSVpreF VE against RSV-associated LRTI. RSVpreF had a favorable safety profile over 2 seasons. Clinical Trials Registration. NCT05035212; EudraCT, 2021-003693-31.
Blue rubber bleb nevus syndrome (BRBNS) is a rare venous malformation syndrome characterised by chronic gastrointestinal bleeding and iron-deficiency anaemia. We report a 79-year-old woman with known BRBNS who presented with overt gastrointestinal bleeding requiring blood transfusion and intravenous iron replacement. Upper and lower gastrointestinal endoscopy failed to reveal a bleeding source while capsule endoscopy demonstrated actively bleeding small-bowel venous malformations. During ongoing evaluation, she developed an ischaemic stroke despite the absence of an identifiable embolic source or inherited thrombophilia. The competing risks of haemorrhage and thrombosis created a significant therapeutic dilemma, necessitating prioritisation of haemorrhage control, with anticoagulation withheld because of the risk of recurrent gastrointestinal bleeding. This case highlights that patients with BRBNS may present with simultaneous thrombotic and haemorrhagic challenges, requiring individualised multidisciplinary management when standard antithrombotic strategies are contraindicated.
Biologic therapies such as monoclonal antibodies are highly effective in reducing disease burden (exacerbations/corticosteroid usage/ hospitalisation) in patients with severe asthma. These medications are currently prohibitively expensive for widespread use compared with standard inhaled and oral therapy. They are indicated for patients with predominantly type 2-high inflammation. Judicious use of biologic therapies in the South African context is imperative given the country's limited healthcare resources. The prescription and clinical use of these therapies within the scope of the South African Health Products Regulatory Authority registered indications therefore require clear guidance and appropriate preparatory optimisation to ensure that the appropriate patients receive the correct medication within an acceptable time frame. Not all patients with difficult-to-treat, or nominally designated as severe, asthma require a biologic therapy in order to be optimally controlled. Simple attention to basic asthma therapeutic principles and treatment of comorbid disease by a clinician with a special interest in asthma may be all that is required. This position statement, written by senior clinicians from the South African Thoracic Society (SATS), is intended to supplement the SATS asthma treatment recommendation of 2021. It provides clear guidance on the appropriate assessment of patients being considered for biologic therapy and clarifies which background medication is required to initiate a biologic therapy in an evidence-based manner. A balanced consideration of side-effects, scientific evidence and cost is essential to prevent unjustified harm to patients by delaying or denying access to biologic therapy. A process to endorse biologic therapy has been created in parallel, and forms are available from SATS, along with registration in the severe asthma registry to support clinicians in appropriate assessment and justification for prescription.
Cancer is a leading global health concern, affecting not only physical health but also psychological, social, emotional and spiritual well-being. Music listening has been explored as a supportive, non-pharmacological intervention within oncology care. The objective of this systematic literature review was to examine the role of music listening in cancer care, focusing on (1) the types of music listening interventions used and (2) the roles and outcomes of such interventions for individuals with cancer. The methods used were a systematic literature review. Literature was systematically searched across Répertoire International de Littérature Musicale (RILM), ScienceDirect, Music Periodicals Database, PsycINFO, Sage Journals, Google Scholar, and PubMed (2000–2024). Inclusion criteria: published literature, peer-reviewed studies involving individuals with cancer and interventions centred on music listening (e.g., pre-recorded, live, guided imagery, and music). Exclusion criteria: non-English, pre-2000, systematic reviews, unpublished literature, meta-analyses, and studies not isolating music listening. Thirteen studies met the criteria. Data were extracted and analysed thematically. Guided imagery and music (GIM), pre-recorded music (e.g., CD/MP3), live music listening, receptive music therapy, music-and-imagery, and group listening session interventions were conducted that ranged from 12 minutes to two hours, most commonly 30 minutes. Intervention outcomes clustered into five themes: (1) symptom reduction (pain, anxiety, depression, nausea), (2) benefits of music listening as a non-pharmacological intervention, (3) coping and enhancement of quality of life, (4) cognitive benefits (memory, distraction from intrusive thoughts, and (5) connectedness (intrapersonal, interpersonal, transpersonal). The conclusions drawn from the results are that music listening is a safe, feasible, cost-effective, and non-invasive adjunct to oncology care. Despite promising results, limitations such as small sample sizes and heterogeneity of study design restrict generalisability. Future research should utilise larger, more rigorous trials, explore digital/streaming music interventions, and evaluate long-term effects.